FlowCardia begins US pivotal study of crosser catheters:
This article was originally published in Clinica
FlowCardia has completed enrolment in a pivotal trial of its Crosser catheters for the treatment of coronary and peripheral chronic total occlusions (CTOs). The trial will analyse the safety and efficacy of the peripheral line of Crosser catheters in lower limb CTOs. The catheters are designed to quickly cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. SunnyVale, California-based FlowCardia is a privately-held firm established in 2002. It entered the US market in January 2006 with its VP wire and VP sheath products (see Clinica No 1189, p18).